Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 12,000 shares at $3.07 ($36K) on 2014-06-04, disclosed to the SEC on 2014-06-06.
Scheduled sale ($36k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.97 | 700 | $2K | 5.7% |
| 2 | $2.98 | 300 | $894 | 2.5% |
| 3 | $3.00 | 11 | $33 | 0.1% |
| 4 | $3.01 | 2,100 | $6K | 17.4% |
| 5 | $3.01 | 900 | $3K | 7.5% |
| 6 | $3.02 | 2,300 |
| $7K |
| 19.1% |
| 7 | $3.02 | 1,200 | $4K | 10.0% |
| 8 | $3.03 | 300 | $909 | 2.5% |
| 9 | $3.03 | 700 | $2K | 5.8% |
| 10 | $3.04 | 1,189 | $4K | 10.0% |
| 11 | $3.04 | 100 | $304 | 0.8% |
| 12 | $3.05 | 700 | $2K | 5.9% |
| 13 | $3.05 | 800 | $2K | 6.7% |
| 14 | $3.06 | 500 | $2K | 4.2% |
| 15 | $3.07 | 200 | $614 | 1.7% |
| Total | $3.02 avg | 12,000 | $36K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |